--- title: "The Market's Island of Misfit Toys: Who's Faking It and Who's Actually Making Money" type: "News" locale: "en" url: "https://longbridge.com/en/news/295081463.md" description: "When you sweep the market's unclassified corners, you get a wild grab bag of legacy media, biotech moonshots, AI-Bitcoin mashups, and a literal corn fund. Amidst the buzzword bingo, a few companies are quietly executing." datetime: "2026-08-06T09:15:07.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295081463.md) - [en](https://longbridge.com/en/news/295081463.md) - [zh-HK](https://longbridge.com/zh-HK/news/295081463.md) --- # The Market's Island of Misfit Toys: Who's Faking It and Who's Actually Making Money There is a corner of the market that always feels like an abandoned luggage sale. You open it up, and you get a bizarre mix of pandemic darlings trying to stay relevant, old-school consumer brands waking from a coma, and companies aggressively pivoting to whatever the 2026 buzzword of the day is. This is stupid and here's why: most of them are throwing spaghetti at the wall. But if you dig through this mismatched group, a couple of them actually have a real business model. Let's start with the adults in the room. The New York Times (NYT.US) is the ultimate example of legacy media refusing to die. While everyone else is crying over AI scraping their content, NYT casually posted USD 762 million in Q2 revenue and beat EPS estimates, boasting over 11.3 million digital subscribers. The stock has been outperforming its peers recently. They figured out the subscription game years ago. Good for them. On the other end of the consumer spectrum, we have Newell Brands (NWL.US). The folks who make Sharpies and Rubbermaid containers just posted their first sales growth in four years—up 2.3% on a core basis, accompanied by a USD 600 million notes offering. Moody's upgraded their outlook. It's moving at a glacial pace, but at least the bleeding has stopped. Then we have the buzzword enthusiasts. Hyperscale Data (GPUS.US) is playing the greatest hits of the 2020s: an AI data center company that mines Bitcoin and just borrowed USD 30 million using a DeFi protocol. They reported roughly USD 80 million in preliminary H1 revenue, up 57%. It sounds like a pitch deck generated by ChatGPT. Good luck with that. Meanwhile, DocuSign (DOCU.US)—the ultimate work-from-home ghost—released its Q1 FY27 results and is frantically trying to stay in the conversation by partnering with Perplexity for AI-automated contract workflows. The stock's recent performance has been middling because just being a digital signature company isn't enough anymore. In the biotech casino, the divergence is stark. BridgeBio Pharma (BBIO.US) is actually making moves. The FDA accepted their NDA for a hypocalcemia drug in July, and backed by a massive USD 1 billion financing deal, analysts are projecting a massive jump in Q2 revenue, giving their recent market performance some solid footing. On the flip side, Vistagen Therapeutics (VTGN.US) is quite literally fighting for its life. The anxiety nasal spray developer just had to beg Nasdaq for a 180-day extension in August because its stock price is struggling to meet the minimum bid requirement. Why aren't you moving faster? The market doesn't wait for science experiments to figure it out. Exagen (XGN.US), however, is quietly executing. Their Q2 autoimmune testing revenue hit a record USD 19.9 million, losses are narrowing, and they bumped up their full-year guidance to USD 72 million. It's no wonder their trajectory looks much healthier this year. Finally, we have the hardcore infrastructure and literal commodities. Terrestrial Energy (IMSR.US) is building next-gen IMSR nuclear reactors in Texas. With Big Tech desperate for clean power, the nuclear narrative is finally making sense. And if you're tired of all this tech and biotech drama, there's always the Teucrium Commodity Trust Corn Fund (CORN.US). It tracks corn. It's up about 3.0% over the last year. It cares about heatwaves, not algorithms. Oh, and Spirit Realty Capital (O.PR.US)? They were swallowed whole by Realty Income in a USD 9.3 billion deal back in 2024, so the preferred shares are just a lingering artifact today. Stop falling for the shiny objects and look at who is actually generating cash. _This article does not constitute investment advice._ ### Related Stocks - [NYT.US](https://longbridge.com/en/quote/NYT.US.md) - [NWL.US](https://longbridge.com/en/quote/NWL.US.md) - [GPUS.US](https://longbridge.com/en/quote/GPUS.US.md) - [DOCU.US](https://longbridge.com/en/quote/DOCU.US.md) - [BBIO.US](https://longbridge.com/en/quote/BBIO.US.md) - [VTGN.US](https://longbridge.com/en/quote/VTGN.US.md) - [XGN.US](https://longbridge.com/en/quote/XGN.US.md) - [IMSR.US](https://longbridge.com/en/quote/IMSR.US.md) - [O.PR.US](https://longbridge.com/en/quote/O.PR.US.md) ## Related News & Research - [New York Times names Robert Barba weekend editor for Metro desk](https://longbridge.com/en/news/295821517.md) - [BridgeBio Stock Has Soared 29% in Just 3 Months. Here's Why Wall Street Thinks It Could Go Even Higher.](https://longbridge.com/en/news/295953255.md) - [Newell Brands announces R$ 0.24 per unit dividend, payable Sept. 21](https://longbridge.com/en/news/295829979.md) - [Jefferies Sticks to Their Buy Rating for BridgeBio Pharma (BBIO)](https://longbridge.com/en/news/295562053.md) - [DocuSign CFO Jeffrey Grayson melepas 15.000 saham senilai $900.000](https://longbridge.com/en/news/295582235.md)